Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373767 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL4587471 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL626770 | 0.98 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6245878 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17685264 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL268638 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL9770059 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL62996 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL16816949 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL14695713 | 0.96 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | MELINTA SUBSIDIARY CORP. | 2018-03-15 | — | — | US | disclosed |
| EP-2603514-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | BCL6B, BCL6, BCR | GPR84 3546/4885FFAR1 1279/4885MAPT 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.